Human milk oligosaccharides (HMOs) are the third most abundant compound in breast milk, CD BioGlyco is focusing on high-quality HMO Production services. Our advanced technology platforms and high-quality services will fully meet your needs.
HMOs are the third most abundant compound in breast milk, but since they cannot be digested by the human gastrointestinal tract, they have no immediate nutritional value. However, several studies have shown that HMOs are important during neonatal development. Milk oligosaccharides interfere with the interaction of bacteria and the host through multiple mechanisms, thereby stimulating the growth of probiotics and constituting the prebiotic function. HMOs have been shown to have anti-adhesive properties. It has been proposed that oligosaccharides mimic the natural ligands of bacteria, thereby occupying their natural binding sites and inhibiting their adhesion. This anti-adhesion property has been described for several bacteria and viruses, including Streptococcus pneumonia, Listeria monocytogenes, Vibrio cholera, Salmonella fyris, HIV, enteropathogenic Escherichia coli, and Campylobacter jejuni.
FLNnH II is a kind of HMO. The chemical structure is shown in Fig.1.
Fig.1 Chemical structure of FLNnH II. (CD BioGlyco)
CD BioGlyco provides a chemoenzymatic method to produce FLNnH II. The enzymes used for the chemoenzymatic synthesis of HMOs are mainly glycosyltransferases (GTs) from pathogenic bacteria such as Helicobacter, Neisseria, or Pasteurella. Fucosylation of HMO structures is performed using GTs cloned from microbial sources. This involves the conversion of GDP-fucose from mannose using recombinant E. coli enzymes, followed by the transfer of GDP-fucose to lactose acceptors. Further enzymatic steps catalyze the synthesis of FLNnH II. For the technology of enzymatic synthesis of oligosaccharides, please refer to Production of HMO by Chemoenzymatic Methods.
There is a need to further evaluate the role of HMO in the in-depth and large-scale characterization of these structures in infants. CD BioGlyco offers a variety of methods for HMO Profiling, including nuclear magnetic resonance (NMR), high pH anion exchange chromatography with pulsed amperometric detection, and mass spectrometry (MS)-based methods (hydrophilic interaction chromatography and porous graphitic carbon separation, coupled or uncoupled MS or stand-alone matrix-assisted laser desorption ionization MS).
CD BioGlyco provides chemoenzymatic methods for FLNnH II production. If you are interested in our services, please contact us for more details without any hesitation.
Reference:
